Moderna, Inc. · ISIN: US60770K1079 · EQS - Company News

Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day

Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day Interim data from Phase 1/2 propionic acidemia (PA) multi-dose Paramount trial shows mRNA-3927 was well-tolerated to date, with encouraging early signs of potential for clinical benefit Interim data from Phase 1/2 glycogen storage disease 1a (GSD1a) single-dose Ba1ance trial shows mRNA-3745 was well tolerated to date, with encouraging early signs of potential for clinical benefit Moderna announces a new development c...

NASDAQ:MRNA Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Moderna, Inc.

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (0)
Short Selling (DE) (0)
Short Selling (UK) (0)
08 September 2022 01:00PM
Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day
US60770K1079
Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day Interim data from Phase 1/2 propionic acidemia (PA) multi-dose Paramount trial shows mRNA-3927 was well-tolerated to date, with encouraging early signs of potential for clinical benefit Interim data from Phase 1/2 glycogen storage disease 1a (GSD1a) single-dose Ba1ance t...
Moderna, Inc.
About the publication
08 September 2022 01:00PM
Moderna, Inc.: Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day
US60770K1079
Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day Interim data from Phase 1/2 propionic acidemia (PA) multi-dose Paramount trial shows mRNA-3927 was well-tolerated to date, with encouraging early signs of potential for clinical benefit Interim data from Phase 1/2 glycogen storage disease 1a (GSD1a) single-dose Ba1ance t...
Moderna, Inc.
About the publication
01 September 2022 03:35PM
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's Omicron-Targeting Bivalent Booster in the European Union
US60770K1079
EMA COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ADOPTS POSITIVE OPINION RECOMMENDING AUTHORIZATION FOR THE USE OF MODERNA’S OMICRON-TARGETING BIVALENT BOOSTER IN THE EUROPEAN UNION Study results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 subvariants when compared with mRNA-127...
Moderna, Inc.
About the publication
01 September 2022 03:35PM
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's Omicron-Targeting Bivalent Booster in the European Union
US60770K1079
EMA COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ADOPTS POSITIVE OPINION RECOMMENDING AUTHORIZATION FOR THE USE OF MODERNA’S OMICRON-TARGETING BIVALENT BOOSTER IN THE EUROPEAN UNION Study results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 subvariants when compared with mRNA-127...
Moderna, Inc.
About the publication
29 August 2022 12:30PM
Moderna, Inc.: Swissmedic Authorizes Moderna’s Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214
US60770K1079
Swissmedic Authorizes Moderna’s Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214 Switzerland becomes among the first countries in the world to approve the use of a next-generation bivalent COVID-19 booster vaccine Study results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 subv...
Moderna, Inc.
About the publication
29 August 2022 12:30PM
Swissmedic Authorizes Moderna’s Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214
US60770K1079
Swissmedic Authorizes Moderna’s Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214 Switzerland becomes among the first countries in the world to approve the use of a next-generation bivalent COVID-19 booster vaccine Study results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 subv...
Moderna, Inc.
About the publication
15 August 2022 01:30PM
Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna's Omicron-Containing Bivalent Booster in the UK
US60770K1079
MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA) AUTHORIZES MODERNA’S OMICRON-CONTAINING BIVALENT BOOSTER IN THE UK Study results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 subvariants when compared with mRNA-1273 CAMBRIDGE, Mass.--(ACCESS WIRE)— AUGUST 15, 2022-- Moderna, In...
Moderna, Inc.
About the publication
15 August 2022 01:30PM
Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna's Omicron-Containing Bivalent Booster in the UK
US60770K1079
MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA) AUTHORIZES MODERNA’S OMICRON-CONTAINING BIVALENT BOOSTER IN THE UK Study results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 subvariants when compared with mRNA-1273 CAMBRIDGE, Mass.--(ACCESS WIRE)— AUGUST 15, 2022-- Moderna, In...
Moderna, Inc.
About the publication
09 August 2022 12:40PM
Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses
US60770K1079
Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses Contractually remaining doses of Moderna's COVID-19 vaccine (Spikevax, mRNA-1273) will be converted to Moderna's next generation Omicron-containing bivalent vaccines CAMBRIDGE, MA / ...
Moderna, Inc.
About the publication
09 August 2022 12:40PM
Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses
US60770K1079
Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses Contractually remaining doses of Moderna's COVID-19 vaccine (Spikevax, mRNA-1273) will be converted to Moderna's next generation Omicron-containing bivalent vaccines CAMBRIDGE, MA / ...
Moderna, Inc.
About the publication
22 July 2022 02:05PM
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union
US60770K1079
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union CAMBRIDGE, MA / July 22, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agenc...
Moderna, Inc.
About the publication
22 July 2022 02:05PM
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union
US60770K1079
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union CAMBRIDGE, MA / July 22, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agenc...
Moderna, Inc.
About the publication
29 April 2022 05:30PM
Moderna Files to Expand Conditional Marketing Authorization for Its COVID-19 Vaccine to Include Children Six Months to Under Six Years in The European Union
US60770K1079
Moderna Files to Expand Conditional Marketing Authorization for Its COVID-19 Vaccine to Include Children Six Months to Under Six Years in The European Union The filing follows the European Medicines Agency's Committee for Medicinal Products for Human Use recent decision to adopt a positive opinion recommending marketing authorization for Moderna's...
Moderna, Inc.
About the publication
21 March 2022 07:00AM
Moderna Announces New Supply Agreement for 2023 with Switzerland for Additional Seven Million Doses of Moderna's COVID-19 Booster Vaccine
US60770K1079
Moderna Announces New Supply Agreement for 2023 with Switzerland for Additional Seven Million Doses of Moderna's COVID-19 Booster Vaccine CAMBRIDGE, MA / ACCESSWIRE / March 21, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new supply agreement with the Swiss...
Moderna, Inc.
About the publication
24 February 2022 05:20PM
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for The Use of The Moderna Covid-19 Vaccine in Children (6-11 Years) In the European Union
US60770K1079
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for The Use of The Moderna Covid-19 Vaccine in Children (6-11 Years) In the European Union Announcement follows CHMP's previous decision to adopt a positive opinion recommending marketing authorization for Moderna's COVID-19 vaccine to incl...
Moderna, Inc.
About the publication
17 February 2022 06:20AM
Moderna, Inc.: Therapeutic Goods Administration of Australia Authorizes Moderna's Covid-19 Vaccine in Children (6-11 Years)
US60770K1079
Therapeutic Goods Administration of Australia Authorizes Moderna's Covid-19 Vaccine in Children (6-11 Years) CAMBRIDGE, MA / ACCESSWIRE / February 16, 2022 / Moderna, Inc., (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia h...
Moderna, Inc.
About the publication
16 February 2022 08:35AM
Moderna and ROVI Expand Long-term Collaboration for the Manufacture of MRNA Medicines Over the Next Ten Years
US60770K1079
MODERNA AND ROVI EXPAND LONG-TERM COLLABORATION FOR THE MANUFACTURE OF MRNA MEDICINES OVER THE NEXT TEN YEARS Long-term agreement includes a series of investments to acquire new equipment and adapt the present ROVI drug product fill-finish facilities and production lines in Spain   CAMBRIDGE, Mass & MADRID.--(ACCESSWIRE)-February 16, 2022-- ...
Moderna, Inc.
About the publication
More Moderna, Inc. related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN